SI
SI
discoversearch

Biotech / Medical
Omeros
An SI Board Since March 2010
Posts SubjectMarks Bans Symbol
449 37 0 OMER
Emcee:  Bradpalm1 Type:  Unmoderated
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction program, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR (G-protein coupled receptor) program, to add an unprecedented number of wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
449SEATTLE--(BUSINESS WIRE)--Jan. 3, 2018-- Omeros Corporation (Nasdaq: OMER) todaynigel bates-January 3
448 Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use finance.yahoo.comJulius Wong-12/13/2017
447Press Release Omeros Corporation to Announce Third Quarter 2017 Financial ResulBiotech Jim-11/6/2017
446Was curious about sales of Omridia. In the area I reside, it does not seem to beD.Lu-11/6/2017
445Bloomberg has this to say last week for products coming up for Pass Through StatBiotech Jim111/5/2017
444I just saw on Twitter that AF is now saying Omridia will lose Medicare pass-thoutuck-11/3/2017
443Deleted Mistaken PostBulbaMan-9/26/2017
442On watch for clear above 21.59. [graphic]hollyhunter-9/20/2017
441OMER responds to AF, a one time event? Some )MS 721 trials info updated here. Biotech Jim-8/23/2017
440A bit different. Prices at 22.75, and asks pop up below that. Decent pricing, scaram(o)uche-8/15/2017
439Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference SEATTLE--(BUHoward Williams-8/10/2017
438 OMER short volume volumebot.comJulius Wong18/9/2017
437Saw the news when it hit and yawned. Now up better than 10%. Own some, have vescaram(o)uche-8/4/2017
436OMER treatment of immunoglobulin A nephropathy granted FDA orphan status theflBiotech Jim18/4/2017
435Omeros Corporation to Announce Second Quarter 2017 Financial Results on August 8Howard Williams-8/2/2017
434>>That's funny on speculation Martin could be Doyle or affiliated. I dBiomaven-7/25/2017
433I realized this after thinking about it. I was in irrational exuberance territoBiotech Jim-7/25/2017
432Just catching up with this thread. The S-8 is routine - that's what is fileBiomaven17/24/2017
431OMEROS' 721: POTENTIAL BLOCKBUSTER FIX FOR IMMUNOGLOBULIN A NEPHROPATHY AlaHoward Williams-7/24/2017
430That's funny on speculation Martin could be Doyle or affiliated. I doubt it rkrw-7/6/2017
429 It’s been speculated that Art Doyle is Martin Shkreli. For example, this SA posBulbaMan-7/6/2017
428He? Art Doyle as in Sir Arthur Doyle? I assume it could be some hedge fund tharkrw17/6/2017
427 Bullish Oneil Trader Omeros article on Seeking Alpha posted today. It mentions BulbaMan-7/6/2017
426I thought it was originally 3 parts now up to 6. I guess he'll look for a pughmm-7/6/2017
425FWIW on that. twitter.comrkrw-7/6/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.